Bristol, Liverpool, Oxford are part of a major new international project to improve our understanding of severe coronavirus infection in humans

Russell Group universities are part of a major new international project, funded by the US Food and Drug Administration (FDA) to improve our understanding of severe coronavirus infection in humans. The three-year project will bring together collaborators from the University of Liverpool, Public Health England, the University of Bristol (Dr David Matthews and Dr Andrew Davidson), the University of Oxford, A*STAR in Singapore, and King Fahd Medical City in Saudi Arabia.

The study will aim to create profiles of various coronaviruses, including SARS-CoV-2 which causes Covid-19, to inform the development of treatments and vaccines. The study will also examine newly developed technologies such as organ-on-chips to rapidly characterise coronaviruses/novel diseases and medical countermeasures.

This international collaboration builds on existing expertise in Russell Group universities while contributing to the global fight against Covid-19. 

Read more: Bristol part of new £4 million FDA study to advance understanding of severe coronavirus infection

Related case studies

Unlocking potential for next-generation medical scanning

Researchers at University of York have developed a new way to magnetise molecules in the human body, paving the way for a new generation of low-cost magnetic resonance imaging (MRI).

Read more >

Tackling air pollution and greenhouse gases with Europe-wide collaboration

Access to a €6.5million Horizon 2020 fund for research on air quality is helping University of Bristol academics influence climate change policy and reduce greenhouse gases and pollution.

Read more >